Emergent BioSolutions entered into a new credit agreement on September 30, 2024 providing for an asset-based revolving loan facility with the lenders party thereto and Wells Fargo Bank, National Association, as administrative agent. The credit agreement provides for revolving loan commitments in an aggregate principal amount up to $100 million with a fixed maturity date of September 30, 2029, subject to early maturity triggers based on the maturity of its other material indebtedness. The new credit facility brings additional liquidity to support Emergent’s multi-year transformation plan. As of September 30, 2024, Emergent had a cash balance of approximately $150 million and undrawn access to $100 million under the ABL.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Newsom signs bill pushing for Narcan in workplace first aid kits, LA Times says
- Amazon to stock Narcan opioid overdose reversal drug at warehouses, WSJ reports
- Emergent BioSolutions announces execution of contract options valued at $67.4M
- Emergent BioSolutions confirms $400M in orders related to smallpox, Mpox
- Study suggests waning mpox protection from Jynneos vaccine, CIDRAP reports